Abstract 486P
Background
Our research group has previously established the cost-effectiveness (CE) of lung cancer screening (LCS) with low-dose computed tomography (LDCT) for both high-risk smokers and non-smokers in Hong Kong (HK). Integrating LCS into the existing infrastructure in HK however requires systematic and rigorous design and execution. Thus, we undertook sensitivity and scenario analyses for LCS beyond fundamental base-case examination. The aim was to explore balance between clinical efficacy and resource optimization for LCS implementation in HK.
Methods
A CE analysis was conducted using decision tree and state-transition Markov model to simulate identification, diagnosis, and treatments for a high-risk population defined by the NELSON study and the TALENT study. One-way sensitivity analysis (OSA) was conducted with ±20% variation of the base-case parameter values. Scenario analyses were undertaken to explore the CE of LCS with varying costs. The incremental cost-effectiveness (ICER) was estimated as costs per quality-adjusted life-year (QALY).
Results
OSA showed that LDCT costs were the main driver for the ICER of LCS targeting heavy smokers, 20% increase in LDCT costs led to an ICER of USD 18,002 (22% higher than base-case ICER). Meanwhile, 20% increase in the treatments costs for stage I LC led to an ICER of 10,844 (7% higher than base-case ICER) for the LCS targeting high-risk non-smokers. Scenario analyses additionally indicated that restraining costs for CT scan, diagnosis, and early-stage LC treatments would yield a reduction in ICER (Table). Table: 486P
Scenario analysis | Smoker | Non smokers | ||
ICER (USD) ∗ | Reduction in ICER ∗ | ICER (USD) | Reduction in ICER | |
Base-case analysis | $14,723 | NA. | $10,096 | NA. |
Cut down unit costs for low-dose CT scans (LDCT) - USD $ 191 | $12,070 | 18% | $9,520 | 6% |
Cut down unit costs for LDCT - USD $ 127 | $9,377 | 36% | $8,934 | 12% |
Cut down unit costs for LDCT - USD $ 64 | $6,684 | 55% | $8,349 | 17% |
Half diagnostic costs for stage I - USD $ 836 (per person) | $14,472 | 2% | $9,635 | 5% |
Half diagnostic costs for stage IV - USD $ 3,922 (per person) | $14,969 | -2% | $8,872 | 12% |
Half treatment costs for the ongoing phase for stage I patients (per 3 months) - USD $ 247 | $13,296 | 10% | $8,777 | 13% |
Half treatment costs for the ongoing phase for stage IV patients (per 3 months) - USD $ 417 | $14,974 | -2% | $10,145 | 0% |
Conclusions
Fiscal restraint on CT scanning and early-stage LC treatments expenditures are necessary to ensure feasible and sustainable LCS implementation in HK. Our findings provide important benchmarks for the HK Government’s consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca Hong Kong.
Disclosure
H.H.F. Loong: Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim, MSD; Financial Interests, Personal, Invited Speaker: Eli Lilly, Illumina, Bayer, Guardant Health; Financial Interests, Personal, Advisory Board: Novartis, Takeda. X. Pan: Financial Interests, Personal, Financially compensated role: i-DNA. All other authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract